FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts



Similar documents
Mobile Medical Application Development: FDA Regulation

CDRH Regulated Software

Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO

CENTER FOR CONNECTED HEALTH POLICY

Mobile Medical Apps. Purpose. Diane Romza Kutz Fredric E. Roth V. Regulation and Risks. Purpose of today s presentation

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

The Shifting Sands of Medical Software Regulation

LIMS and workflow integration as impulse to establish Virtual Microscopy to daily clinical use

Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories

Regulatory Considerations for Medical Device Software. Medical Device Software

What is a medical device? Medical Devices: Roadmap to Market. Kathryn Klaus, Esq.

Medical Device Software

Mobile Medical Applications

Developing a Mobile Medical App? How to determine if it is a medical device and get it cleared by the US FDA

US & CANADA: REGULATION AND GUIDELINES ON MEDICAL SOFTWARE AND APPS OR

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Mobile Medical Applications: FDA s Final Guidance. M. Elizabeth Bierman Anthony T. Pavel Morgan, Lewis & Bockius, LLP

FDA Regulation of Hearing Aids. Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic and ENT Devices ODE/CDRH/FDA

Regulation of Mobile Medical Apps

ILLINOIS DEPARTMENT OF CENTRAL MANAGEMENT SERVICES CLASS SPECIFICATION CLINICAL LABORATORY TECHNICIAN SERIES

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

Adekunle M Adesina, M.D., Ph.D

VENTANA Digital Pathology. Reliable. Efficient. Comprehensive.

Final Document. Software as a Medical Device (SaMD): Key Definitions. Date: 9 December Despina Spanou, IMDRF Chair. IMDRF/SaMD WG/N10FINAL:2013

Datrix, Inc NOV Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

CDRH Regulated Software Looking back, looking forward

Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff

Pros & Cons of Digital Pathology

Medical Device Software: Establishing FDA Authority and Mobile Medical Apps

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices

We Believe the Possibilities. Delphic AP

Factors Influencing LC/MS/MS Moving into Clinical and Research Laboratories

Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions

General Wellness: Policy for Low Risk Devices. Draft Guidance for Industry and Food and Drug Administration Staff

[DOCKET NO.96N-0002] DRAFT

2014 Annual Report on Inspections of Establishments

How To Know If A Mobile App Is A Medical Device

Cutting Edge Issues in Health Care Technology & mhealth. Agenda

PMAs, 510(k)s, and Advanced IDE Topics

How To Regulate A Medical Device From A Cell Phone

ORACLE CONSULTING GROUP

Document issued on April 13, The draft of this document was issued on April 23, 2014.

Interoperability between Anatomic Pathology Laboratory Information Systems and Digital Pathology Systems

JOINT COMMISSION INTERNATIONAL ACCREDITATION STANDARDS FOR. 2nd Edition

MAR (k) SUMMARY OF SAFETY AND EFFECTIVENESS (21CFR ) 1. DATE PREPARED: 4/21/2008

March 19, Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

MViAKIO. V.A hn2 ATTACHMENT I 610(K) SUMMARY. Submitter:

Preparation "Clinical Laboratory Technologist and Technician Overview"

Diagnostic Tests. Brad Spring Director, Regulatory Affairs

Combination Products Regulation in the United States

Regulatory Issues in Genetic Testing and Targeted Drug Development

University of Texas Medical School at Houston. April 14, 2015

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)

The U.S. FDA s Regulation and Oversight of Mobile Medical Applications

Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. 1

What Does Having a FDA Cleared Pregnancy Test Mean?

PREP Course #27: Medical Device Clinical Trial Management

Medical Product Software Development and FDA Regulations Software Development Practices and FDA Compliance

JUL Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA

SMF Awareness Seminar 2014

Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions

Prepublication Requirements

FDA Issues Final Guidance on Mobile Medical Apps

Dear Ms. Lucas: This letter corrects our substantially equivalent letter of February 18, 2016.

International Medical Device Regulators Forum (IMDRF) US FDA Center for Devices and Radiological Health - Update

On Behalf of: InTouch Health

How to apply for Medical Device License in Taiwan

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices

UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES

L~l t l V~! MAY ?

O c t o b e r Digital Pathology

Delphic AP. Designer software for your pathology workflow. We Believe the Possibilities.

Medical Device Regulatory Requirements for Taiwan

0 EC V-,) 133 Lj9a

Regulated Mobile Applications

Health Care Job Information Sheet #13. Laboratory

January 12, Dear Amy Yang:

Q(K SVJM~jPagelIof 3

DICOM Grid, Inc. January 25, Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

Building 6, Suite 300 RyeBrook, NY C-ontact-N~ame: --- William H-. Schofield Director of TeleHealth Operations. Signal,_Radiofrequency

CAP Accreditation Checklists 2015 Edition

Medical Software Development. International standards requirements and practice

D I Z1. 510(k) Summary. Section 5. Siemens Medical Solutions USA, Inc. Oncology Care Systems. Date Prepared: September 09,

AgaMatrucx. NV2 21 Salem, NH oz (k) Sumnmary

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

Security of Medical Device Applications

February 5, Dear Kristin Pabst,

Transcription:

FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts Clinical Laboratory Improvement Advisory Committee Meeting Centers for Disease Control and Prevention February 15, 2012 Tremel A. Faison, MS, RAC, SCT(ASCP) FDA/CDRH/OIVD/DIHD 1

Outline Regulation of Medical Devices Safety and Effectiveness Intended Use Device Classification Digital Pathology/Whole Slide Imaging Systems Define History of digital imaging in vitro diagnostics (IVDs) WSI risk and benefits: classification Major clinical study design challenges 2

Center for Devices and Radiological Health (CDRH) Responsible for regulating firms who manufacture, repackage, relabel, and/or import medical devices sold in the United States 3

What is a medical device? 5 MP digital camera Captures still images or videos LCD display at 320 x 240 resolution Three objectives with magnification from 40X-400X 2 built-in light sources 128 MB memory A clinical intended use would make this a medical device! 4

In vitro diagnostics (IVDs) Reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. 21CFR809.33 5

Determination of safety and effectiveness 21 CFR 860.7 Intended use population Conditions of use for the device Probable benefit to health from the use of the device weighed against any probable injury of illness Reliability of the device 6

Safety Safety and Effectivenss There is reasonable assurance that the probable benefits outweigh any probable risks. [21CFR860.7(d)(1)] Effectiveness There is reasonable assurance that the use of the device will provide clinically significant results. [21CFR860.7(e)(1)] 7

Device Classification Appropriate level of regulatory control that is necessary to assure safety and effectiveness. Classification is risk-based and determined based upon the intended use of the device. 8

Intended Use/Indications for Use A general description of the disease or condition the device will diagnose, treat, prevent, cure, or mitigate, including a description of the patient population for which the device is intended. 21 CFR 814.20 (b)(3)(i) 9

Device classification Class III Highest risk General Controls Premarket Approval (PMA) Class II Moderate risk General Controls and Special controls Premarket notification (510(k)) Substantial equivalence to a predicate Class I Low risk General controls (GMP) 510(k) exempt Registration and listing 10

Digital Pathology The use of computer technology to convert analog microscopic images into digital images Whole slide imaging (WSI), aka digital imaging, virtual slides, virtual microscopy System consisting of hardware; microscope, camera, scanner, computer, and monitor, and software. Encompasses image acquisition, processing, archiving and retrieval 11

Scope of this presentation Use of whole slide imaging (WSI) for primary surgical pathology diagnosis in lieu of optical microscope Will not cover: image analysis, biomarkers cytopathology or hematology research or educational use 12

21 CFR 864.3600 Microscopes and accessories Optical instruments used to enlarge images of specimens, preparations, and cultures for medical purposes Class I (general controls) exempt from premarket notification (510k) subject to limitations in 864.9. 13

21 CFR 864.9 Limitations of exemptions from 510(k) (a few) Exemption only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. The following would not be exempt: Different fundamental scientific technology IVD intended for use in diagnosis, monitoring or screening of neoplastic diseases 14

What does this mean? SLIDE Conventional optical microscope Mechanical scanner Light source Imaging optics Digital image sensor Image Processing software Display IMAGE DATA FILES Microscope just one component of the system Image acquisition, processing and display new technology for this intended use Diagnostic for neoplastic disease WSI systems can not be considered Class I exempt READER 15

IVD devices that utilize digital imaging Class III Gynecologic Cytology Imaging Systems Class II Automated hematology analyzers (differential cell counters) Chromosome analyzers FISH enumeration systems Urine sediment analyzers Immunohistochemistry image analysis (Her2, ER, etc) Manual Read of Digital Image (PR, Her2) 16

Regulatory Pathway for WSI Same intended use as microscope New technology trips limitations to exemption from premarket notification Not Class II, no predicate: currently cleared devices have specific and limited intended uses that are not applicable to WSI for the breadth of surgical pathology specimens FDA does not currently see how risk can be mitigated through special controls WSI are systems and are not considered, by definition, as laboratory developed tests (LDT) WSI raises new questions of safety and effectiveness that must answered through premarket approval (PMA) (Class III) 17

How does FDA plan to ensure the safety and effectiveness of digital pathology devices? Knowledge of the risks and benefits Require non-clinical and clinical studies to objectively and precisely validate performance Clearly state limitations of WSI Standardization 18

What are the potential benefits? Will WSI improve patient care? Faster turnaround time? Increased productivity? Easier retrieval of images and archiving? Improve workflow? Review when pathologist not on-site (telepathology) and consultation Integration of image with patient s electronic medical record Image analysis algorithms Simultaneous viewing of images side by side 19

What are the risks? Is the WSI presented of such that equally good or better quality diagnoses could be made as when using the light microscope for all surgical pathology specimens? Differences in human interaction between the two methods, i.e. viewing and navigating on a computer screen vs. a light microscope Serious consequences to public health if misdiagnosis is caused by poor quality image or improper use as surgical pathology diagnosis is the final answer for most conditions 20

Major Clinical Study Design Challenges Clinical studies must support intended use in intended use population. Need adequate supporting evidence since potential change in pathological practice. Broad applications for WSI. How to carve the domain of pathological specimens to provide a realistic and manageable approach without significant concerns of off-label use? Potential use of information obtained from the non-clinical study to guide clinical study design. 21

Major Clinical Study Design Challenges, con t: Intended Use Statement Primary Diagnosis FFPE tissue, Frozen Section. H & E, Special Stains, IHC. Reasonable intended use population 22

Major Clinical Study Design Challenges, con t: Prospectively designed study Case selection: Prospective and/or retrospective Potential case enrichment Evaluate accuracy, not agreement 23

Major Clinical Study Design Challenges, con t: Evaluating Diagnostic Accuracy Clinical Reference Standard (Expert Panel) Participants diagnoses by light microscopy Participants diagnoses by WSI 24

Major Clinical Study Design Challenges, con t Reader selection: representative of intended user Paired Design Randomized read order Sufficient washout period Blinding/Masking Components and level of diagnostic detail assessed 25

Recently Published Guidance Documents relevant to Digital Pathology Research Use Only (RUO) Guidance Devices labeled RUO that have not been approved or cleared by the FDA as medical devices, should only be used in research and not for clinical diagnosis of patients IUO is a label that should ONLY be found on an approved IDE device or one under IRB approval, so this could be used for diagnosis, but should never be sold and should not be used after the clinical study period and should never be used off-label. Mobile Medical Application Guidance Mobile platforms such as ipads, smart phones, etc. "mobile medical app" is a mobile app that meets the definition of "device" in section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)4; and either: is used as an accessory to a regulated medical device; or transforms a mobile platform into a regulated medical device 26

Thank You! 27